4//SEC Filing
Bedrosian Camille L 4
Accession 0000950170-24-045693
CIK 0001658551other
Filed
Apr 17, 8:00 PM ET
Accepted
Apr 18, 8:19 PM ET
Size
7.2 KB
Accession
0000950170-24-045693
Insider Transaction Report
Form 4
Bedrosian Camille L
Chief Medical Officer
Transactions
- Award
Common Stock
2024-04-16+96,910→ 155,243 total - Award
Stock Option (Right to Buy)
2024-04-16+120,000→ 120,000 totalExercise: $2.01Exp: 2034-04-15→ Common Stock (120,000 underlying)
Footnotes (2)
- [F1]The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest as follows: 33% on September 30, 2024, 33% on March 31, 2025 and 34% on September 30, 2025, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
- [F2]25% of the shares subject to the option shall vest and become exercisable on April 16, 2025, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
Documents
Issuer
Amylyx Pharmaceuticals, Inc.
CIK 0001658551
Entity typeother
Related Parties
1- filerCIK 0001326969
Filing Metadata
- Form type
- 4
- Filed
- Apr 17, 8:00 PM ET
- Accepted
- Apr 18, 8:19 PM ET
- Size
- 7.2 KB